Impact of alternative efficacy end point definitions on reported outcomes after ablation of paroxysmal atrial fibrillation – Insights from the COMPARE-CRYO study using continuous rhythm monitoring
Alternative efficacy end point definitions have a significant impact on reported outcomes and health care utilization metrics after AF ablation. These findings are important when considering end point definitions other than the traditional 30 seconds in the design of future AF-ablation trials.
Authors
- Philipp Krisai (ORCID: https://orcid.org/0000-0002-4367-2363)
- Laurent Roten (ORCID: https://orcid.org/0000-0002-0827-1329)
- Thomas Kueffer (ORCID: https://orcid.org/0000-0003-3553-4945)
- Helge Servatius (ORCID: https://orcid.org/0000-0003-2887-8707)
- Salik ur Rehman Iqbal (ORCID: https://orcid.org/0000-0001-6361-1130)
- Dik Heg (ORCID: https://orcid.org/0000-0002-8766-7945)
- Gregor Thalmann (ORCID: https://orcid.org/0000-0002-2050-6311)
- Michael Kühne (ORCID: https://orcid.org/0000-0002-2937-3711)
- Patrick Badertscher (ORCID: https://orcid.org/0000-0001-9751-0557)
- Jens Maurhofer (ORCID: https://orcid.org/0000-0003-4442-8941)
- Sven Knecht (ORCID: https://orcid.org/0000-0001-7122-021X)
- Hildegard Tanner (ORCID: https://orcid.org/0000-0001-9722-5617)
- Christian Sticherling (ORCID: https://orcid.org/0000-0001-8428-7050)
- Tobias Reichlin (ORCID: https://orcid.org/0000-0002-7197-8415)
- Corinne Jufer
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
- University Hospital of Basel (CH)
Publication Details
- Journal
- Heart Rhythm
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.hrthm.2025.09.026
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Foundation for Cardiovascular Research
- Universität Basel
- Boston Scientific Corporation
- University of Bern
- Inselspital, Universitätsspital Bern
- Daiichi Sankyo Europe